Stifel is serving as exclusive financial advisor to Minghui
PR Newswire news releases · 2026-11-04 14:30
View evidence
- CompanyPR Newswire news releases2026-11-04 14:30
Stifel is serving as exclusive financial advisor to Minghui
View source
Company
Company
No. 15082 of 118934top 13%down 7912 places this week
3 direct links
In a group of 78 closely linked entities, around
Weighted by public relations with evidence, recomputed daily.
Arrows show the direction of the relationship. Filter to focus on a business area.
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.View source
Stifel is serving as exclusive financial advisor to MinghuiView source
Fangda Partners is serving as legal advisor.View source
Showing 1 to 3 of 3
Read the assertion alongside its sources. Expand a row to inspect the evidence.
Stifel is serving as exclusive financial advisor to Minghui
PR Newswire news releases · 2026-11-04 14:30
Stifel is serving as exclusive financial advisor to MinghuiView source
Fangda Partners is serving as legal advisor.
PR Newswire news releases · 2026-11-04 14:30
Fangda Partners is serving as legal advisor.View source
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.
PR Newswire news releases · 2026-11-04 14:30
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.View source
Minghui will receive an upfront payment of USD 110 million
PR Newswire news releases · 2026-11-04 14:30
Minghui will receive an upfront payment of USD 110 millionView source
as well as tiered royalties up to mid-30% on net sales in Japan.
PR Newswire news releases · 2026-11-04 14:30
as well as tiered royalties up to mid-30% on net sales in Japan.View source
Showing 1 to 5 of 5
Valuation data is available on Pro and Research.
Included in ProKnow a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.
Not available: Company signals · Financials · Filings · Sites · Guidance